Jeffrey Thomas  Perez net worth and biography

Jeffrey Perez Biography and Net Worth

SVP of Precigen
Mr. Jeffrey Perez serves as Senior Vice President, Intellectual Property Affairs for Precigen. Before joining the company, Mr. Perez was with Third Security LLC, where he evaluated potential investments of Third Security’s managed investment funds. Additionally, Mr. Perez worked with Third Security portfolio companies in evaluating and developing their intellectual property strategies and general corporate activities. Prior to joining Third Security, Mr. Perez practiced intellectual property law with the law firm of Hunton & Williams LLP in Washington D.C. Mr. Perez’s previous work involved client consultation, litigation, agreement work, opinion drafting and patent procurement. Mr. Perez received a BS degree from Cornell University and JD from George Mason University School of Law.

What is Jeffrey Thomas Perez's net worth?

The estimated net worth of Jeffrey Thomas Perez is at least $603,989.24 as of August 9th, 2024. Mr. Perez owns 743,097 shares of Precigen stock worth more than $603,989 as of November 5th. This net worth approximation does not reflect any other investments that Mr. Perez may own. Additionally, Mr. Perez receives a salary of $540,670.00 as SVP at Precigen. Learn More about Jeffrey Thomas Perez's net worth.

How old is Jeffrey Thomas Perez?

Mr. Perez is currently 52 years old. There are 7 older executives and no younger executives at Precigen. The oldest executive at Precigen is Mr. Randal J. Kirk J.D., Executive Chairman, who is 71 years old. Learn More on Jeffrey Thomas Perez's age.

What is Jeffrey Thomas Perez's salary?

As the SVP of Precigen, Inc., Mr. Perez earns $540,670.00 per year. There are 2 executives that earn more than Mr. Perez. The highest earning executive at Precigen is Dr. Helen Sabzevari MPH, Ph.D., President, CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on Jeffrey Thomas Perez's salary.

How do I contact Jeffrey Thomas Perez?

The corporate mailing address for Mr. Perez and other Precigen executives is 20374 Seneca Meadows Parkway, Germantown MD, 20876. Precigen can also be reached via phone at (301) 556-9900 and via email at [email protected]. Learn More on Jeffrey Thomas Perez's contact information.

Has Jeffrey Thomas Perez been buying or selling shares of Precigen?

Jeffrey Thomas Perez has not been actively trading shares of Precigen during the last quarter. Most recently, on Friday, August 9th, Jeffrey Thomas Perez bought 58,823 shares of Precigen stock. The stock was acquired at an average cost of $0.85 per share, with a total value of $49,999.55. Following the completion of the transaction, the senior vice president now directly owns 743,097 shares of the company's stock, valued at $631,632.45. Learn More on Jeffrey Thomas Perez's trading history.

Who are Precigen's active insiders?

Precigen's insider roster includes Randal Kirk (Director), Donald Lehr (Insider), David Obstler (CFO), Jeffrey Perez (SVP), Helen Sabzevari (CEO), and Harry Thomasian, Jr. (CFO). Learn More on Precigen's active insiders.

Are insiders buying or selling shares of Precigen?

In the last year, Precigen insiders bought shares 2 times. They purchased a total of 155,509 shares worth more than $186,326.81. The most recent insider tranaction occured on August, 9th when SVP Jeffrey Thomas Perez bought 58,823 shares worth more than $49,999.55. Insiders at Precigen own 44.9% of the company. Learn More about insider trades at Precigen.

Information on this page was last updated on 8/9/2024.

Jeffrey Thomas Perez Insider Trading History at Precigen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/9/2024Buy58,823$0.85$49,999.55743,097View SEC Filing Icon  
8/24/2023Sell8,891$1.64$14,581.24458,903View SEC Filing Icon  
8/17/2023Sell8,741$1.55$13,548.55448,916View SEC Filing Icon  
8/10/2023Sell8,956$1.21$10,836.76438,779View SEC Filing Icon  
8/3/2023Sell8,789$1.20$10,546.80428,857View SEC Filing Icon  
1/27/2023Buy28,571$1.75$49,999.25381,012View SEC Filing Icon  
5/17/2022Sell14,778$1.28$18,915.84333,502View SEC Filing Icon  
1/5/2022Sell9,738$3.59$34,959.42View SEC Filing Icon  
1/3/2022Sell5,022$3.67$18,430.74View SEC Filing Icon  
1/5/2021Sell9,049$10.56$95,557.44288,870View SEC Filing Icon  
12/16/2020Sell9,382$7.20$67,550.40268,229View SEC Filing Icon  
9/16/2020Sell7,660$5.22$39,985.20250,889View SEC Filing Icon  
1/2/2020Sell4,366$5.60$24,449.6066,705View SEC Filing Icon  
10/1/2019Sell4,521$5.50$24,865.5056,886View SEC Filing Icon  
8/11/2017Buy1,000$17.89$17,890.0012,537View SEC Filing Icon  
See Full Table

Jeffrey Thomas Perez Buying and Selling Activity at Precigen

This chart shows Jeffrey Thomas Perez's buying and selling at Precigen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Precigen Company Overview

Precigen logo
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Read More

Today's Range

Now: $0.82
Low: $0.80
High: $0.84

50 Day Range

MA: $0.95
Low: $0.79
High: $1.15

2 Week Range

Now: $0.82
Low: $0.79
High: $1.93

Volume

707,590 shs

Average Volume

950,035 shs

Market Capitalization

$208.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68